A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

Summary

A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.

Timeline

Start

2006-12

Primary completion

2008-10

Completion

2008-10

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Ocriplasmin 25µg vs Placebo; p = 0.796; NCT00412958 ↗

registry analysis (superiority or other test); Ocriplasmin 75µg vs Placebo; p = 0.447; NCT00412958 ↗

registry analysis (superiority or other test); Ocriplasmin 125µg vs Placebo; p = 0.107; NCT00412958 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ocriplasmin	Protein / enzyme biologic	25 ug	Intravitreal
Subject	Ocriplasmin	Protein / enzyme biologic	75 ug	Intravitreal
Subject	Ocriplasmin	Protein / enzyme biologic	125 ug	Intravitreal

Indications

No indication recorded.